Srinivas Akkaraju

Director · Alumis

Srinivas Akkaraju (Director) filed 12 Form 4 reports in the trailing twelve months (12 purchases, 1 sale, 2 filed past the two-business-day deadline; 1 filing reported both), most often in Alumis Inc. (ALMS). Across 11 priced purchase filings, the average 21-session return was +35.0% from execution and +27.3% from disclosure (delay-adjusted; derived). The largest single filing was $11.9M of SRRK (287,970 sh across 4 lots, as filed), executed Oct 23. Data as of Nov 8 2026.

Add to watchlist

Return, ttmiAverage return per filing, trailing twelve months

+35.0%

avg across 11 priced filings

Delay-adjustediThe same average, entered at disclosure dates

+27.3%

same 11 filings, from disclosure

Filings, ttm

12 buys · 1 sells · 2 late

Median delay

execution → disclosure

Volume, ttmiDollar value disclosed in the trailing twelve months

$46.2M

shares × price, as filed

Last traded

Oct 26

Filed Oct 27

Median ADV $31.6M across their filed names

Impact on $10,000 · 12M

$15,239 (+52.4%)

S&P 500 $10,907 (+9.1%) · 43.3 pts ahead

Srinivas Akkaraju S&P 500

Derived: compounded across filings from disclosure dates · past 12 months

Open performance→

Volume by month

Buys $92.5M Sells $1.0M

Shares × price, as filed · by filing month · past 24 months

Sectors filed on

Healthcare 12 filings

Sector per market data · by filing · past 12 months

Most traded names

ALMS

Alumis Inc. ALMS · 9 buys · 1 sell 9 filings SRRK

Scholar Rock Holding Corporation SRRK · 3 buys · 0 sells 3 filings KLRS

Kalaris Therapeutics, Inc. KLRS · 2 buys · 0 sells 2 filings MLYS Mineralys Therapeutics, Inc. MLYS · 2 buys · 0 sells 2 filings NGNE

Neurogene Inc. NGNE · 1 buy · 0 sells 1 filing

Recent filings

SRRKPURCHASE Scholar Rock Holding Corporation View filing → $11.9M
287,970 sh across 4 lots
Exec Oct 23
Filed Oct 27 · 7:47 PM ET ALMSSALE Alumis Inc. View filing → $1.0M
96,131 sh across 2 lots
Exec Sep 8
Filed Sep 9 · 9:39 PM ET ALMSPURCHASE Alumis Inc. View filing → $10.7M
986,721 sh across 4 lots
Exec Sep 4
Filed Sep 9 · 9:39 PM ET KLRSPURCHASE Kalaris Therapeutics, Inc. View filing → $1.2M
244,300 sh × $4.83
Exec May 20
Filed May 22 · 7:47 PM ET ALMSPURCHASE Alumis Inc. View filing → $10.0M
588,235 sh × $17.00
Exec Jan 9
Filed Jan 13 · 6:20 PM ET KLRSPURCHASE Kalaris Therapeutics, Inc. View filing → $5.0M
479,847 sh × $10.42
Exec Dec 18 2025
Filed Feb 17 · 8:15 PM ET † ALMSPURCHASE Alumis Inc. View filing → $1.8M
186,377 sh across 3 lots
Exec Dec 5 2025
Filed Dec 9 2025 · 7:13 PM ET ALMSPURCHASE Alumis Inc. View filing → $2.0M
262,027 sh across 3 lots
Exec Dec 2 2025
Filed Dec 4 2025 · 8:11 PM ET More filings →